INMB
INmune Bio, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.39
P/S
654.00
EV/EBITDA
-0.29
DCF Value
$0.76
FCF Yield
-74.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-94766.0%
Net Margin
-91866.0%
ROE
-171.0%
ROA
-142.0%
ROIC
-188.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-5.3M | $1.72 |
| FY 2025 | $50.0K | $-45.9M | $0.00 |
| Q3 2025 | $0.00 | $-6.5M | $-0.24 |
| Q2 2025 | $0.00 | $-24.5M | $-1.05 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.89
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.